ibi115
Small Cell Lung Cancer (SCLC)
Innovent Biologics (Suzhou) Co. Ltd.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
290 Active assets in the Small Cell Lung Cancer (SCLC) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Benmelstobart Yayi He | Phase 4 | A |
vx-970 National Cancer Institute (NCI) | Phase 2 | BBB |
Adebelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | BBB |
Veliparib Central European Society for Anticancer Drug Research | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →